-
6 Months In, Trump Has Filled Only 27 Out Of More Than 200 Envoy Posts, Mostly With Cronies
Saturday, July 22, 2017 - 3:27pm | 836Read More...President Donald Trump fired some 200 top envoys upon his inauguration and has only filled 27 posts so far, mostly with political cronies who contributed to his campaign. Trump’s appointment of Jon Huntsman, former governor of Utah and a former ambassador to China and to Singapore, fits...
-
Exclusive: Wealth-X President On Expanding Ultra High-Net-Wealthy Population And Spending Habits
Tuesday, June 7, 2016 - 3:50pm | 400Read More...In an exclusive interview with Benzinga, Wealth-X Co-Founder and President, David Friedman, discussed the expanding and changing ultra-high wealthy population and how they affect luxury markets. Wealth-X is a provider of custom market research, specializing in analyzing the ultra high-net-worth...
-
UPDATE: Morgan Stanley Reiterates On Theravance As Slow Trends Weigh On Value
Monday, July 21, 2014 - 10:09am | 175Read More...In a report published Monday, Morgan Stanley analyst David Friedman reiterated an Underweight rating on Theravance (NASDAQ: THRX), but lowered the price target from $12.00 to $7.00. In the report, Morgan Stanley noted, “In light of the THRX/TBPH split, we are updating our model for Royalty Co. (we...
-
UPDATE: Morgan Stanley Reiterates On Idenix Pharmaceuticals Due To Likely Merck Acquisition
Tuesday, June 10, 2014 - 9:34am | 111Read More...In a report published Tuesday, Morgan Stanley analyst David Friedman reiterated an Equal-Weight rating on Idenix Pharmaceuticals (NASDAQ: IDIX), and raised the price target from $5.00 to $24.50. In the report, Morgan Stanley noted, “We are increasing our price target to $24.50 in light of Merck's...
-
UPDATE: Morgan Stanley Reiterates On Incyte On ASCO Abstracts
Thursday, May 15, 2014 - 9:14am | 98Read More...In a report published Thursday, Morgan Stanley analyst David Friedman reiterated an Underweight rating on Incyte (NASDAQ: INCY), but removed the $14.00 price target. In the report, Morgan Stanley noted, “OS and PFS data trended together and seem to be generating a clinically meaningful pt benefit...
-
UPDATE: Morgan Stanley Reiterates On Theravance Following Anoro Launch
Thursday, May 15, 2014 - 8:58am | 113Read More...In a report published Thursday, Morgan Stanley analyst David Friedman reiterated an Underweight rating on Theravance (NASDAQ: THRX), but removed the $12.00 price target. In the report, Morgan Stanley noted, “Anoro (Umec/VI) recently launched in the US. In light of the slow Breo launch, Street...
-
GW Pharma Soars 35% on Initiation from Morgan Stanley, Bullish Comments by Jim Cramer
Tuesday, April 22, 2014 - 9:06am | 165Read More...On Tuesday, Morgan Stanley initiated coverage on shares of GW Pharmaceuticals (NASDAQ: GWPH) with an Overweight rating and $103 price target, sending the shares $15 higher to $61. Analyst David Friedman believes the company's cannabis platform “has strong potential, with the epilepsy program...
-
UPDATE: Morgan Stanley Reiterates on Synageva BioPharma as Brain-Blood Barrier Study is Good Next Step
Tuesday, April 1, 2014 - 8:29am | 119Read More...In a report published Tuesday, Morgan Stanley analyst David Friedman reiterated an Overweight rating on Synageva BioPharma (NASDAQ: GEVA), but removed the $118.00 price target. In the report, Morgan Stanley “Synageva recently started an MPS3b pt study (n=6) where they will be assessing the degree...
-
UPDATE: Morgan Stanley Reiterates on Chimerix as New AdV Trial Highlights Broad Brincidofovir Potential
Wednesday, March 12, 2014 - 8:47am | 133Read More...In a report published Wednesday, Morgan Stanley analyst David Friedman reiterated an Overweight rating on Chimerix (NASDAQ: CMRX), but removed the $34.00 price target. In the report, Morgan Stanley noted, “Chimerix announced today that based on urgent patient need, they have negotiated with the...
-
UPDATE: Morgan Stanley Downgrades Auxilium Pharmaceuticals as Growth May Not Match High Valuation
Thursday, March 6, 2014 - 8:11am | 164Read More...In a report published Thursday, Morgan Stanley analyst David Friedman downgraded the rating on Auxilium Pharmaceuticals (NASDAQ: AUXL) from Equal-Weight to Underweight, but reiterated the $15.00 price target. In the report, Morgan Stanley noted, “We are DG AUXL to UW from EW as we do not believe...
-
UPDATE: Morgan Stanley Initiates Coverage on Ultragenyx Pharmaceutical on Growing Orphan Drug Pipeline
Tuesday, February 25, 2014 - 8:47am | 159Read More...In a report published Tuesday, Morgan Stanley analyst David Friedman initiated coverage on Ultragenyx Pharmaceutical (NASDAQ: RARE) with an Overweight rating and $81.00 price target. In the report, Morgan Stanley noted, “Ultragenyx is an orphan disease focused co. that has in-licensed a series of...
-
Morgan Stanley Expects Theravance to Continue to Underperform Following 4Q Earnings
Friday, February 7, 2014 - 9:28am | 91Read More...In a report published Friday, Morgan Stanley analyst David Friedman reiterated an Underweight rating and $13.00 price target on Theravance (NASDAQ: THRX). In the report, Morgan Stanley noted, “THRX is still planning for a split by 1Q14. While we await details on the ultimate capital structure and...
-
UPDATE: Morgan Stanley Downgrades Alnylam Pharmaceuticals, Sees Robust Drug Prospects
Tuesday, January 14, 2014 - 10:53am | 165Read More...In a report published Tuesday, Morgan Stanley analyst David Friedman downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Overweight to Equal-weight and raised its price target to $72.00 from $54.00. According to the report, the move was based on a more balanced risk/reward post recent stock...
-
UPDATE: Morgan Stanley Downgrades Neurocrine Biosciences on Recent Stock Appreciation
Wednesday, January 8, 2014 - 8:32am | 141Read More...In a report published Wednesday, Morgan Stanley analyst David Friedman downgraded Neurocrine Biosciences (NASDAQ: NBIX) to EqualWeight from OverWeight, raising its price target to $16.00. According to the report, the price target increase is based on a set of model changes including adding VMAT...
-
UPDATE: Morgan Stanley Initiates Coverage on Relypsa on Large Opportunity in K+ Control
Tuesday, December 10, 2013 - 8:59am | 191Read More...In a report published Tuesday, Morgan Stanley analyst David Friedman initiated coverage on Relypsa (NASDAQ: RLYP) with an Overweight rating and $57.00 price target. In the report, Morgan Stanley noted, “We are OW Relypsa as we believe patiromer has $850+mn revenue potential in hyperK+. Patiromer...
